Vivozon Completes Dosing in Phase 1 Clinical Trial of Drug Addiction Treatment ‘VVZ-2471’ in Korea

Vivozon's drug addiction treatment pipeline is progressing smoothly.

Vivozon announced on the 25th that it has completed dosing of subjects in the ongoing Phase 1 clinical trial of VVZ-2471 in South Korea.

VVZ-2471 is an oral new drug candidate developed by Vivozon to treat drug addiction-related disorders, including opioid use disorder. After completing a single-dose escalation study in March and confirming safety and tolerability up to high doses, Vivozon has now completed dosing in the multiple-dose escalation study.

This Phase 1 clinical trial was conducted at Seoul National University Bundang Hospital with healthy adult males in a randomized, double-blind, placebo-controlled design. In the multiple-dose study, safety and tolerability of all dose levels were confirmed through evaluations by a Data Safety Monitoring Board (DSMB) composed of specialists at each dose escalation stage, and the pharmacokinetic characteristics of repeated oral dosing were tested to design the Phase 2 clinical trial.

A company representative stated, “We have now completed all multiple-dose studies and are in the process of verifying the collected data. Narcotic drug abuse such as opioid addiction is becoming a serious personal and social issue in South Korea, and we expect VVZ-2471 to be an alternative for prevention, treatment, and alleviation of withdrawal symptoms of drug addiction.” They added, “VVZ-2471 has also demonstrated efficacy in neuropathic pain animal models, raising expectations for its development as an oral analgesic.”

Meanwhile, Vivozon is expanding its pipeline specialized in central nervous system disorders following its main pipeline VVZ-149 (Opiranserin). The Opiranserin injectable is currently undergoing pre-review by the Ministry of Food and Drug Safety for domestic product approval, and the degenerative nerve disease treatment VVZ-3416 has entered preclinical development.

This content was produced with the assistance of AI translation services.